Mohini Ranganathan, MBBS
Associate Professor of PsychiatryCards
About
Research
Publications
2025
The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review
Shafie M, Ing K, Rostam‐Abadi Y, Weleff J, Griffin M, Ranganathan M, Aghaei A, Pratt N, Funaro M, Nia A. The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review. Addiction Biology 2025, 30: e70047. PMID: 40415392, PMCID: PMC12104536, DOI: 10.1111/adb.70047.Peer-Reviewed Original ResearchConceptsOpioid use disorderOUD outcomesUse disorderConditioned place preference paradigmPlace preference paradigmReducing withdrawal symptomsPotential of cannabidiolSubstance use disordersEfficacy of cannabidiolTreatment of opioid use disorderPreclinical studiesClinical studiesOpioid use disorder treatmentPreference paradigmAnxiety symptomsWithdrawal symptomsPsychiatric disordersEffective treatment approachTreatment optionsHuman studiesCannabidiolAnimal studiesSystematic reviewShort-term follow-upCraving478. Cross-Site Quality Assessment of Data From a Pharmacologic Neuroimaging Trial Targeting Working Memory Neural Circuits in Schizophrenia
Zharyy C, Fonteneau C, Rahmati M, Price A, Gil R, Govil P, Grinband J, Gur R, Haubold N, Heffernan Z, Lu J, Mayer M, Ranganathan M, Santamauro N, Tamayo Z, Van Snellenberg J, Wolf D, Group T, Anticevic A, Lieberman J, Kantrowitz J, Abi-Dargham A, Gur R, Krystal J, Cho Y. 478. Cross-Site Quality Assessment of Data From a Pharmacologic Neuroimaging Trial Targeting Working Memory Neural Circuits in Schizophrenia. Biological Psychiatry 2025, 97: s294. DOI: 10.1016/j.biopsych.2025.02.716.Peer-Reviewed Original Research
2024
Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study
Mohammad Aghaei A, Urban Spillane L, Pittman B, Flynn L, De Aquino J, Bassir Nia A, Ranganathan M. Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study. Psychopharmacology 2024, 241: 2145-2155. PMID: 38832949, DOI: 10.1007/s00213-024-06625-6.Peer-Reviewed Original ResearchRey Auditory Verbal Learning TestCannabis use disorderHuman laboratory studiesOral tetrahydrocannabinolPsychoactive effectsSex differencesAuditory Verbal Learning TestDissociative Symptoms ScalePsychotomimetic States InventoryExposure to cannabisVerbal Learning TestPlacebo-controlledIncreased cannabis useInvestigate sex differencesClinician-AdministeredVerbal learningPsychotomimetic effectsCannabinoid effectsLearning TestCannabis useTetrahydrocannabinol dosesEffects of sexUse disorderDose-related effectsIndividual vulnerabilityClinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.
Pfeiffer P, Geller J, Ganoczy D, Jagusch J, Carty J, Festin F, Gilmer W, Martis B, Ranganathan M, Wiechers I, Hosanagar A. Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38206011, DOI: 10.4088/jcp.23m14984.Peer-Reviewed Original ResearchConceptsPHQ-9 scoresKetamine infusionClinical outcomesSymptom improvementInfusion frequencyPatient Health Questionnaire-9 scoreVeterans Health Administration electronic medical recordsBaseline PHQ-9 scoreShort-term clinical trialsAntidepressant medication trialsFirst ketamine infusionIntravenous ketamine treatmentMonths of infusionFrequency of infusionsMinority of patientsVA health systemWeeks of treatmentRoutine clinical practiceMajor depressive disorderNumber of infusionsElectronic medical recordsIntravenous ketamineKetamine treatmentFirst infusionMedication trials
2023
Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing
Martin A, Ranganathan M, D’Souza D. Cannabis Causes Positive, Negative, and Cognitive Symptoms and Produces Impairments in Electrophysiological Indices of Information Processing. 2023, 156-166. DOI: 10.1017/9781108943246.017.Peer-Reviewed Original ResearchMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsHealth teamsImpact of exposureCognitive symptomsCannabis dependenceAdverse effectsCannabisSynthetic cannabinoidsIllnessPsychosisCannabinoidsElectrophysiological indicesNew research findingsAssociationComplex associationSymptomsPutative modelNeurodevelopmentSchizophreniaImpairment
2015
Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis.
D'Souza D, Cortes-Briones J, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson R, Skosnik P. Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2015, 1: 60-67. PMID: 29560896, DOI: 10.1016/j.bpsc.2015.09.008.Peer-Reviewed Original Research
Clinical Trials
Current Trials
M1 Schizophrenia PET Study
HIC ID2000031171RoleSub InvestigatorPrimary Completion Date04/30/2023Recruiting ParticipantsGenderBothAge18 years - 55 yearsSchizophrenia Spectrum Biomarkers Consortium (SSBC)
HIC ID2000029485RolePrincipal InvestigatorPrimary Completion Date12/31/2030Recruiting ParticipantsA longitudinal study of the effects of cannabis exposure on neuro-development in adolescents and young adults
HIC ID2000024543RoleSub InvestigatorPrimary Completion Date01/31/2021Recruiting ParticipantsGenderBothAge13 years - 25 yearsSleep Dependent Learning in Schizophrenia and Psychosis Risk Syndrome
HIC ID1201009524RoleSub InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18 years - 55 yearsImaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
HIC ID1005006735RoleSub InvestigatorPrimary Completion Date12/31/2016Recruiting ParticipantsGenderMaleAge18 years - 55 years
Academic Achievements & Community Involvement
News
News
- February 28, 2025Source: Yale Ventures
YSM Faculty Win Awards From the Blavatnik Fund for Innovation at Yale
- December 12, 2024Source: Yale Ventures
Yale Life Science PitchFest 2024 Showcases Groundbreaking Research and Innovation
- November 25, 2024
Yale Center for the Science of Cannabis and Cannabinoids Announces Inaugural Pilot Award Winners
- July 15, 2024Source: Blavatnik Family Foundation
Eight Pioneering Innovations Honored with Blavatnik Accelerator Awards at the 2024 Yale Innovation Summit